AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30115087 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow in my Green Food Steps programme (Intervention)
Number of subjects: 602
Study 30115087 — intervention group
Group type: COMPARATOR
Intervention: Control (no information provided)
Number of subjects: 602
Study 27142462 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation (SCT)
Number of subjects: 89
Study 27142462 — intervention group
Group type: COMPARATOR
Intervention: Melphalan plus dexamethasone
Number of subjects: 89
Study 27142462 — intervention group
Group type: COMPARATOR
Intervention: Matched analysis (SCT vs melphalan plus dexamethasone)
Number of subjects: 89
Study 25740399 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 109
Study 25740399 — intervention group
Group type: COMPARATOR
Intervention: Carperitide
Number of subjects: 109
Study 23403087 — intervention group
Group type: EXPERIMENTAL
Intervention: TCRE plus gestagen
Number of subjects: 71
Study 23403087 — intervention group
Group type: COMPARATOR
Intervention: TCRE alone
Number of subjects: 71
Study 20620365 — intervention group
Group type: EXPERIMENTAL
Intervention: Lava Frame 0.3 mm thick
Number of subjects: 9
Study 20620365 — intervention group
Group type: EXPERIMENTAL
Intervention: Lava Frame 0.5 mm thick
Number of subjects: 9
Study 20620365 — intervention group
Group type: COMPARATOR
Intervention: Lithium disilicate glass-ceramic (control)
Number of subjects: 9
Study 20620365 — intervention group
Group type: EXPERIMENTAL
Intervention: All ZrO(2) copings
Number of subjects: 9
Study 18632272 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-tactile vestibular substitution system (EVSS)
Number of subjects: 12
Study 18632272 — intervention group
Group type: COMPARATOR
Intervention: No-EVSS
Number of subjects: 12
Study 15913898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral coping skills therapy combined with pharmacotherapy
Number of subjects: 80
Study 12421055 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller-group search
Number of subjects: 6
Study 12421055 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit instructions to limit search to a specific feature
Number of subjects: 6
Study 12421055 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottom-up factors
Number of subjects: 6
Study 10340838 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/day aspirin (n = 9399)
Number of subjects: 18790
Study 10340838 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9391)
Number of subjects: 18790
Study 10340838 — intervention group
Group type: EXPERIMENTAL
Intervention: Target DBP < or = 90 mmHg (n = 6264)
Number of subjects: 18790
Study 10340838 — intervention group
Group type: EXPERIMENTAL
Intervention: Target DBP < or = 85 mmHg (n = 6264)
Number of subjects: 18790
Study 10340838 — intervention group
Group type: EXPERIMENTAL
Intervention: Target DBP < or = 80 mmHg (n = 6262)
Number of subjects: 18790
Study 7594023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 408
Study 1823041 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd-YAG laser treatment
Number of subjects: 117
Study 7025334 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (6 weeks in a rehabilitation centre followed by home continuation)
Number of subjects: 39
Study 7025334 — intervention group
Group type: COMPARATOR
Intervention: Control group (attended rehabilitation centre after the controlled part of the study)
Number of subjects: 39
Study 30232627 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium curettes (TC)
Number of subjects: 8
Study 30232627 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel ultrasonic tip (PS)
Number of subjects: 8
Study 30232627 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythritol air-polishing powder (EP)
Number of subjects: 8
Study 30232627 — intervention group
Group type: COMPARATOR
Intervention: Rubber cup polishing (CON)
Number of subjects: 8
Study 27957785 — intervention group
Group type: EXPERIMENTAL
Intervention: 2R/2R genotype of thymidylate synthase (TS)
Number of subjects: 615
Study 27957785 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-2R/2R genotypes)
Number of subjects: 615
Study 25676904 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 139
Study 25676904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 24417878 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message with attained outcomes
Number of subjects: 0
Study 24417878 — intervention group
Group type: COMPARATOR
Intervention: Other message frames (gain-framed, loss-framed with undesirable outcomes, etc.)
Number of subjects: 0
Study 21674768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone-sulbactam (CS) 100 mg/kg/day
Number of subjects: 55
Study 21674768 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (PIP/TAZO) 360 mg/kg/day
Number of subjects: 55
Study 19358075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisone injection
Number of subjects: 57
Study 19358075 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetics injection
Number of subjects: 57
Study 17440204 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of noise (negative noise) in social-ecological interaction
Number of subjects: 0
Study 17440204 — intervention group
Group type: COMPARATOR
Intervention: No noise (control condition)
Number of subjects: 0
Study 11190521 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon-J-pouch anal anastomosis (CPAA)
Number of subjects: 66
Study 11190521 — intervention group
Group type: COMPARATOR
Intervention: Straight side-to-end colo-anal anastomosis (CAA)
Number of subjects: 66
Study 3161813 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated estrogens (CE) daily
Number of subjects: 17
Study 3161813 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of intramuscular depomedroxyprogesterone acetate (DMPA) every 3 months
Number of subjects: 17
Study 3161813 — intervention group
Group type: COMPARATOR
Intervention: Premenopausal controls
Number of subjects: 17
Study 30538063 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-admission cholecystectomy
Number of subjects: 249
Study 30538063 — intervention group
Group type: COMPARATOR
Intervention: Delayed cholecystectomy (after 2 weeks)
Number of subjects: 249
Study 29055158 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.85% UMEC
Number of subjects: 23
Study 29055158 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 23
Study 28383836 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium 110/50 μg (IND/GLY) once daily
Number of subjects: 0
Study 28383836 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/proprionate of fluticasone 50/500 μg (SAL/FC) twice daily
Number of subjects: 0
Study 25047458 — intervention group
Group type: EXPERIMENTAL
Intervention: edoxaban 15 mg once daily
Number of subjects: 264
Study 25047458 — intervention group
Group type: EXPERIMENTAL
Intervention: edoxaban 30 mg once daily
Number of subjects: 264
Study 25047458 — intervention group
Group type: COMPARATOR
Intervention: enoxaparin 2000 IU (20 mg) twice daily
Number of subjects: 264
Study 22171728 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT), 6 sessions
Number of subjects: 58
Study 22171728 — intervention group
Group type: COMPARATOR
Intervention: Nutrition-focused attention-matched control group (CG), 6 sessions
Number of subjects: 58
Study 22171728 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CBT and CG)
Number of subjects: 58
Study 20686456 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (RLAI)
Number of subjects: 666
Study 20686456 — intervention group
Group type: COMPARATOR
Intervention: Oral quetiapine
Number of subjects: 666
Study 18454611 — intervention group
Group type: EXPERIMENTAL
Intervention: Single music therapy intervention
Number of subjects: 25
Study 18454611 — intervention group
Group type: COMPARATOR
Intervention: Volunteer visit (control group)
Number of subjects: 25
Study 16162051 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype-consistent views
Number of subjects: 0
Study 16162051 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype-inconsistent views
Number of subjects: 0
Study 16162051 — intervention group
Group type: EXPERIMENTAL
Intervention: High affiliative motivation
Number of subjects: 0
Study 16162051 — intervention group
Group type: EXPERIMENTAL
Intervention: Social distance motives
Number of subjects: 0
Study 12527977 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-Pre (75 g glucose dissolved in 500 ml water, ingested 15 min before exercise)
Number of subjects: 8
Study 12527977 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-Pre (75 g glucose dissolved in 500 ml water, ingested 45 min before exercise)
Number of subjects: 8
Study 12527977 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-Pre (75 g glucose dissolved in 500 ml water, ingested 75 min before exercise)
Number of subjects: 8
Study 12527977 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-Pre
Number of subjects: 8
Study 12527977 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-Pre
Number of subjects: 8
Study 12527977 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-Pre
Number of subjects: 8
Study 12527977 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-Pre, 45-Pre, 75-Pre
Number of subjects: 8
Study 10231449 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (17 mg/kg/min over 30 min)
Number of subjects: 35
Study 10231449 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (1.0 microgram/kg/min over 30 min)
Number of subjects: 35
Study 10231449 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 35
Study 8910967 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold models applied in methadone programme evaluation
Number of subjects: 0
Study 1907091 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose alone
Number of subjects: 7
Study 1907091 — intervention group
Group type: COMPARATOR
Intervention: Glucose-lipid mixture
Number of subjects: 7
Study 29077900 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 87
Study 29077900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 27466218 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (EXE) twice daily (BID)
Number of subjects: 69
Study 27466218 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (GLAR)
Number of subjects: 69
Study 24342024 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step attendance during years 1 and 5
Number of subjects: 1945
Study 24342024 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment duration
Number of subjects: 1945
Study 23216646 — intervention group
Group type: EXPERIMENTAL
Intervention: NicVAX® co-administered with varenicline (Champix®)
Number of subjects: 600
Study 23216646 — intervention group
Group type: COMPARATOR
Intervention: placebo co-administered with varenicline (Champix®)
Number of subjects: 600
Study 20405011 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed highly-active antiretroviral therapy (DOT)
Number of subjects: 1000000
Study 20405011 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered HAART
Number of subjects: 1000000
Study 20405011 — intervention group
Group type: COMPARATOR
Intervention: No HAART
Number of subjects: 1000000
Study 20405011 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed therapy (DOT)
Number of subjects: 1000000
Study 18676757 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-CEA/B7.1 vaccine followed by chemotherapy (group 1)
Number of subjects: 118
Study 18676757 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-CEA/B7.1 vaccine with tetanus toxoid adjuvant followed by chemotherapy (group 2)
Number of subjects: 118
Study 18676757 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by ALVAC-CEA/B7.1 vaccine (group 3)
Number of subjects: 118
Study 18676757 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (all groups)
Number of subjects: 118
Study 18676757 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (group 3)
Number of subjects: 118
Study 16425972 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol monotherapy
Number of subjects: 45
Study 16425972 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol plus UVA1 phototherapy
Number of subjects: 45
Study 16425972 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol plus narrow-band UVB phototherapy
Number of subjects: 45
Study 15463842 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg twice daily with routine treatment for four months
Number of subjects: 30
Study 15463842 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment alone
Number of subjects: 30
Study 10816408 — intervention group
Group type: EXPERIMENTAL
Intervention: Buscopan (hyoscine-N-butylbromide) 20 mg administered before barium infusion (Group A)
Number of subjects: 100
Study 10816408 — intervention group
Group type: COMPARATOR
Intervention: Buscopan (hyoscine-N-butylbromide) 20 mg administered after barium infusion and gas insufflation (Group B)
Number of subjects: 100
Study 8666605 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (800 centigray dose)
Number of subjects: 85
Study 8666605 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation (800 centigray dose)
Number of subjects: 85
Study 1876282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amino acid infusion (90 min)
Number of subjects: 24
Study 1876282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amino acid infusion (30 min)
Number of subjects: 24
Study 1876282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amino acid infusion (both protocols)
Number of subjects: 24
Study 1876282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amino acid infusion
Number of subjects: 24
Study 6871775 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 2% solution
Number of subjects: 20
Study 6871775 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 5% solution
Number of subjects: 20
Study 6871775 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 30721937 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 966
Study 30721937 — intervention group
Group type: COMPARATOR
Intervention: Non-LNS (multiple micronutrient (MMN) + iron and folic acid (IFA))
Number of subjects: 966
Study 27795368 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI4893 at 225 mg
Number of subjects: 33
Study 27795368 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI4893 at 750 mg
Number of subjects: 33
Study 27795368 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI4893 at 2,250 mg
Number of subjects: 33
Study 27795368 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI4893 at 5,000 mg
Number of subjects: 33
Study 27795368 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI4893
Number of subjects: 33
Study 27795368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 26651384 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized foot orthoses
Number of subjects: 0
Study 25170833 — intervention group
Group type: EXPERIMENTAL
Intervention: GH(67) (67 µg/kg/day)
Number of subjects: 111
Study 25170833 — intervention group
Group type: COMPARATOR
Intervention: GH(33×1) (33 µg/kg/day)
Number of subjects: 111
Study 25170833 — intervention group
Group type: EXPERIMENTAL
Intervention: GH(67×1) (67 µg/kg/day)
Number of subjects: 111
Study 25170833 — intervention group
Group type: EXPERIMENTAL
Intervention: GH(33×2) (67 µg/kg/day)
Number of subjects: 111
Study 25170833 — intervention group
Group type: EXPERIMENTAL
Intervention: GH(67)
Number of subjects: 111
Study 25170833 — intervention group
Group type: COMPARATOR
Intervention: GH(33)
Number of subjects: 111
Study 23082835 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic warnings showing cosmetically important harm caused by smoking
Number of subjects: 56
Study 23082835 — intervention group
Group type: COMPARATOR
Intervention: Written smoking warnings alone
Number of subjects: 56
Study 18615103 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) treatment
Number of subjects: 22
Study 17683094 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based therapy
Number of subjects: 80
Study 17683094 — intervention group
Group type: COMPARATOR
Intervention: Individual-supportive psychotherapy
Number of subjects: 80
Study 15449046 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-h IDEX SPECT scan
Number of subjects: 12
Study 15449046 — intervention group
Group type: COMPARATOR
Intervention: 0-h IDEX SPECT scan
Number of subjects: 12
Study 15449046 — intervention group
Group type: COMPARATOR
Intervention: 3-h IDEX SPECT scan
Number of subjects: 12
Study 15449046 — intervention group
Group type: COMPARATOR
Intervention: 24-h IDEX SPECT scan
Number of subjects: 12
Study 15449046 — intervention group
Group type: EXPERIMENTAL
Intervention: IDEX SPECT
Number of subjects: 12
Study 15449046 — intervention group
Group type: COMPARATOR
Intervention: MR imaging
Number of subjects: 12
Study 12222721 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized sleep programme with therapist support
Number of subjects: 67
Study 12222721 — intervention group
Group type: COMPARATOR
Intervention: Written information only during the first intervention
Number of subjects: 67
Study 9472974 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 150 mg
Number of subjects: 16
Study 9472974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7617236 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam 0.1 mg x kg‐1 + oral clonidine 5 micrograms x kg‐1 (Group B)
Number of subjects: 30
Study 7617236 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam 0.1 mg x kg‐1 + i.m. clonidine 4 micrograms x kg‐1 (Group C)
Number of subjects: 30
Study 7617236 — intervention group
Group type: COMPARATOR
Intervention: Oral diazepam 0.1 mg x kg‐1 (Group A)
Number of subjects: 30
Study 2611446 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU of salmon calcitonin nasal spray (sCT‐NS)
Number of subjects: 11
Study 2611446 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU of salmon calcitonin nasal spray (sCT‐NS)
Number of subjects: 11
Study 2611446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 330322 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + triamterene treatment with or without methyldopa
Number of subjects: 0
Study 330322 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of hypotensive therapy
Number of subjects: 0
Study 330322 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive therapy
Number of subjects: 0
Study 31123057 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) therapy at flows of 8-2 L/min
Number of subjects: 44
Study 31123057 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) therapy
Number of subjects: 44
Study 31343947 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acid supplementation (EAAs) - 20 g, twice daily for 7 days before TKA and for 6 weeks after surgery
Number of subjects: 41
Study 31343947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 28086853 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counselor delivered pedometer‐mediated walking intervention (6 sessions over 8-10 weeks)
Number of subjects: 0
Study 28086853 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (informational brochure and a pedometer)
Number of subjects: 0
Study 28086853 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counselor delivered pedometer‐mediated walking intervention
Number of subjects: 0
Study 26950740 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous talc
Number of subjects: 80
Study 26950740 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 23258530 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose pegylated interferon (IFN)
Number of subjects: 1319
Study 21323251 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious-mood induction (video of interviews with frontline nurses and doctors during the SARS epidemic)
Number of subjects: 30
Study 21323251 — intervention group
Group type: COMPARATOR
Intervention: Calm-mood induction (video of a nursing student's pleasant orientation to a clinical placement site)
Number of subjects: 30
Study 19338588 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% benzophenone‐4
Number of subjects: 94
Study 19338588 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% benzophenone‐4
Number of subjects: 94
Study 19338588 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% methylene bis‐benzotriazolyl tetramethylbutylphenol
Number of subjects: 94
Study 16703971 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal injection of hypertonic dextrose (50% dextrose and 0.25% Bupivacaine)
Number of subjects: 0
Study 15155329 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg succinylcholine
Number of subjects: 100
Study 15155329 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg succinylcholine
Number of subjects: 100
Study 15155329 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg succinylcholine
Number of subjects: 100
Study 15155329 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg succinylcholine
Number of subjects: 100
Study 15155329 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg succinylcholine
Number of subjects: 100
Study 11205409 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin Disease Prevention Program (SDPP) including individual skin care and protection regimes, skin care and protection products, and seminars.
Number of subjects: 29
Study 9701409 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (median dose 250 mg twice daily; range 250-375 mg twice daily)
Number of subjects: 0
Study 9701409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8124700 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.3% sodium fluoride varnish
Number of subjects: 274
Study 8124700 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1% sodium fluoride varnish
Number of subjects: 274